Aurinia Pharmaceuticals Reports Financial Results for the Three and Nine Months Ended September 30, 2026 and Provides Update on Recent Business Progress

What happened

Aurinia Pharmaceuticals reported total revenue of $83.7 million for the three months and $244.6 million for the nine months ended September 30, 2026. Net product sales of LUPKYNIS were $79.4 million and $232.4 million for those periods.

Confirmed

Global impact / market context

LUPKYNIS is the main revenue driver, so its 12% and 18% sales growth lifts total revenue and net income. Higher sales spread fixed costs, which can improve profit per sale and give the company more cash available for operations.

Analyst inference

Investors may compare LUPKYNIS sales growth with total revenue growth to judge reliance on the drug. License and royalty revenue, though smaller, grew faster at 54% and 39%, which may signal added diversification beyond direct product sales.

Analyst inference

What to watch

1. Net income before taxes rose 21% to $38.7 million for the quarter and 67% to $131.4 million for the nine months, which means profit grew faster than revenue over the longer period. Confirmed
2. Management could face questions on whether LUPKYNIS sales growth can continue and whether faster-growing license and royalty revenue becomes a larger share of total revenue. Proposed
3. Watch whether rising revenue converts into cash available for capital spending or debt reduction, since higher net income does not automatically mean more cash on hand. Analyst inference

Evidence

• Original source link unavailable